Navigation Links
U.S. Genomics Inc. Receives $4.5 Million Investment from BD
Date:9/23/2008

- Enters Strategic Collaboration for Development of Novel Infectious

Disease Diagnostic Platform -

WOBURN, Mass., Sept. 23 /PRNewswire/ -- U.S. Genomics today announced it has received a $4.5 million equity investment from BD (Becton, Dickinson and Company) and that the companies have entered into a strategic collaboration for development of a novel infectious disease diagnostic platform. The collaboration will focus on application of U.S. Genomics' DirectLinear Analysis(TM) technology (DLA) for the detection of a wide range of infectious organisms in a single molecular diagnostic test. A diagnostic platform based on DLA has the potential to provide information to physicians concerning pathogen identity, virulence and drug resistance within hours, as opposed to the multi-day techniques such as culturing, plating, and staining that are done today.

U.S. Genomics has invested in excess of $50 million in DLA technology, which integrates novel labeling strategies, advanced microfluidics and optical engineering to enable pathogens to be identified by rapidly analyzing individual DNA molecules present in a clinical sample. The technology is capable of simultaneously detecting a broad range of infectious organisms in a single diagnostic test. A diagnostic test based on DLA has the potential to provide clinicians and doctors' information important for patient health, such as which drugs a specific pathogen may be resistant to, and which drugs could be used for most effective patient treatment.

"We are very pleased to enter into this strategic relationship with BD," said John J. Canepa, U.S. Genomics' CEO. "BD is the clear market leader in clinical microbiology and their deep experience in product development is an ideal complement to our innovative DLA technology and strong research team. We share the goal of establishing a new, faster, more accurate capability for microbial diagnostics, based on genotype, leading to more effective patient treatment and better outcomes."

DLA technology, developed with support from venture capital investors, NSF, DARPA, and the U.S. Department of Homeland Security (DHS), also has the potential to be applied in applications such as patient screening, hospital monitoring, epidemiology and forensics. U.S. Genomics currently has an extremely sensitive and accurate sensor for detection of biological threats in development under the DHS Bioagent Autonomous Network Detector program. Similar precision is required in hospital settings, where regulations may restrict reimbursement for costs associated with certain infections that occur as a result of hospital procedures. DLA has the potential to rapidly and accurately resolve whether a patient who became sick during a hospital stay was infected with a known hospital-based organism, or a strain not previously seen.

"We see tremendous potential for application of DLA technology," Canepa continued. "Working closely with BD on this collaboration, we plan to prioritize development efforts toward the multi-billion dollar infectious disease testing market. Further, the flexibility of the DLA technology to address a wide range of sample types creates future opportunities for U.S. Genomics to expand into significant new application areas, such as bio- security, bio-surveillance, and environmental and food safety testing."

About U.S. Genomics, Inc.

U.S. Genomics is pioneering single molecule biology technologies for diagnostics and biodefense applications by combining advanced microfluidics, optical engineering, and novel labeling strategies. Using its DNA mapping technology, the Company is developing sophisticated biological sensors for the detection and identification of pathogens and biomarkers in the air and other biologically relevant materials. The Company's biodefense focus on airborne pathogens has been funded in part by contracts from the U.S. Department of Homeland Security Science and Technology Directorate. U.S. Genomics' portfolio of products will further a greater understanding of genetics and disease pathways leading to more effective use of therapeutics, and a range of diagnostics, and biodefense applications. For more information, please visit http://www.usgenomics.com


'/>"/>
SOURCE U.S. Genomics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
4. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
5. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
6. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
7. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
8. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
9. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
10. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... 2017 , ... The Giving Tree Wellness Center announces the ... of consumers who are incorporating medical marijuana into their wellness and health regimens. ... operators of two successful Valley dispensaries, The Giving Tree’s two founders, Lilach Mazor ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially ... cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their own facilities, ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, October 24th, ABC² ... the first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker will be ... and open to the public, but registration is required. , WHAT: ABC² ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
(Date:4/18/2017)...  Socionext Inc., a global expert in SoC-based imaging and computing ... M820, which features the company,s hybrid codec technology. A demonstration utilizing ... Inc., will be showcased during the upcoming Medtec Japan at Tokyo ... Las Vegas Convention Center April 24-27. ... Click here for an image ...
Breaking Biology News(10 mins):